Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Intravenous Immunoglobulin Market Share, Size, Forecast, Trends, Growth, Analysis: By Form: Liquid, Lyophilised; By Product: IGG, IGA, IGM, IGE, IGD; By Indication; By Distribution Channels; By End Use; Regional Analysis; Market Dynamics; Competitive Landscape; Key Trends and Developments in the Market; 2023-2028

Global Intravenous Immunoglobulin Market Outlook 

The global intravenous immunoglobulin market is expected to grow at a CAGR of 6.90% between 2023 and 2028. The market is being driven by increasing prevalence of immunodeficiency diseases and rising adoption of intravenous immunoglobulin treatments.  

 

Key Trends in the Market 

Intravenous immunoglobulin or IVIG is a therapy treatment targeted towards patients deficient of antibodies that would otherwise fight infections or are suffering from autoimmune diseases. Immunoglobulins are prepared by the immune system of people who are healthy and have sufficient antibodies. IVIG treatment response varies from person to person, and there is a likelihood that some patients may not respond to the treatment.

 

  • A wide number of conditions can be treated with IVIG therapy. The increasing adoption rate for the intravenous immunoglobulin therapy because of the safety and efficacy it provides is expected to drive the growth of the intravenous immunoglobulin market.
  • COVID-19 has impacted the health of the people and weakening the immune systems of many worldwide. Intravenous immunoglobulin therapy treatment can prove effective in such cases, by boosting the weakened immune systems.
  • Intravenous immunoglobulin therapy may be cost prohibitive as it is a long-term therapy with costs varying depending upon the severity of the original condition. Lowering costs are a key trend for the global market for intravenous immunoglobulin that can support its long term growth.
  • Geriatric populations are also likely to have weakened immune systems, increasing their susceptibility to other illnesses. IVIG treatment can help improve the health of such populations, increasing their overall lifespan.

 

Market Analysis 

Based on form, the intravenous immunoglobulin market can be bifurcated into liquid and lyophilised. On the basis of product the market can be divided into IGG, IGA, IGM, IGE, and IGD. Based on indication, the market is segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP),  Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, and chronic lymphocytic leukaemia, among others. 

 

By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. Based on end use the market is divided into hospitals, clinics, and home care. The regional markets can be categorised into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.  

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global intravenous immunoglobulin market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

 

  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Biotest AG
  • LFB S.A
  • Others

 

Market Share by Form

The liquid form segment of the intravenous immunoglobulin market accounts for a substantial share, due to the ease of administering liquids intravenously, without concerns of mixing powders in required concentrations. Liquid immunoglobulin is collected from the blood plasma of the individuals only after screening them and making sure that they are healthy. The blood plasma collected is purified and is tested for serious infections such as AIDS and hepatitis. 

 

Lyophilised or powder form of intravenous immunoglobulin is administered within 2-3 hours of its dissolution. It offers greater flexibility in changing dosages for patients new to the treatment and trying out various concentrations to find an ideal match. 

 

Market Share by End Use

Intravenous immunoglobulin is typically given to patients in hospitals or clinics but in some cases it can be administrated through home care, under careful supervision of a professional nurse. As IVIG treatment tends to be long-term, many patients start out with treatments in hospitals or clinics, and later moving on to home care. 

 

Administration of intravenous immunoglobin through home care is preferable for long-term treatment as it is more comfortable for patients to receive treatment in the comfort of their own home, due to which growth of the home care segment in the intravenous immunoglobulin market is expected. Depending upon the region and insurance coverage, home care may or may not be more expensive than receiving intravenous immunoglobin in hospitals or clinics. 

 

Competitive Landscape 

CSL Limited founded in 1916 has its headquarter in Melbourne, Australia. This biotechnology company mainly focusses on innovating medical solutions to treat bleeding disorders, neurological disorders, and other disorders or medical problems. 

 

Grifols, S.A. was established in 1940 and has its headquarter in Barcelona, Spain. It is a pharmaceutical and chemical manufacturer known for the development of blood-plasma based products. It also supplies reagents, devices, and instruments for laboratories involved in clinical testing.

 

Octapharma AG was incorporated in 1983 and has its headquarter in Lachen, Switzerland. It is a family owned company and develops human proteins from human cell lines and plasma. They typically manufacture products that treat bleeding disorders and other rare diseases. 

 

Other market players include Shanghai RAAS Blood Products Co., Ltd., Biotest AG, and LFB S.A, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Form
  • Product
  • Indication
  • Distribution Channels
  • End Use
  • Region
Breakup by Form
  • Liquid
  • Lyophilised
Breakup by Product
  • IGG
  • IGA
  • IGM
  • IGE
  • IGD
Breakup by Indication
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukaemia
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by End Use
  • Hospitals
  • Clinics
  • Home Care
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Biotest AG
  • LFB S.A
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Intravenous Immunoglobulin Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Intravenous Immunoglobulin Historical Market (2018-2022) 
    8.3    Global Intravenous Immunoglobulin Market Forecast (2023-2028)
    8.4    Global Intravenous Immunoglobulin Market by Form
        8.4.1    Liquid
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
        8.4.2    Lyophilised
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
    8.5    Global Intravenous Immunoglobulin Market by Product 
        8.5.1    IGG
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    IGA
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
        8.5.3    IGM
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2018-2022)
            8.5.3.3    Forecast Trend (2023-2028)
        8.5.4    IGE
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2018-2022)
            8.5.4.3    Forecast Trend (2023-2028)
        8.5.5    IGD
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2018-2022)
            8.5.5.3    Forecast Trend (2023-2028)
    8.6    Global Intravenous Immunoglobulin Market by Indication
        8.6.1    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022)
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Idiopathic Thrombocytopenic Purpura (ITP)
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022)
            8.6.2.3    Forecast Trend (2023-2028)
        8.6.3    Guillain-Barre Syndrome
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2022)
            8.6.3.3    Forecast Trend (2023-2028)
        8.6.4    Myasthenia Gravis
            8.6.4.1    Market Share
            8.6.4.2    Historical Trend (2018-2022)
            8.6.4.3    Forecast Trend (2023-2028)
        8.6.5    Multifocal Motor Neuropathy (MMN)
            8.6.5.1    Market Share
            8.6.5.2    Historical Trend (2018-2022)
            8.6.5.3    Forecast Trend (2023-2028)
        8.6.6    Kawasaki Disease
            8.6.6.1    Market Share
            8.6.6.2    Historical Trend (2018-2022)
            8.6.6.3    Forecast Trend (2023-2028)
        8.6.7    Hypogammaglobulinemia
            8.6.7.1    Market Share
            8.6.7.2    Historical Trend (2018-2022)
            8.6.7.3    Forecast Trend (2023-2028)
        8.6.8    Chronic Lymphocytic Leukaemia
            8.6.8.1    Market Share
            8.6.8.2    Historical Trend (2018-2022)
            8.6.8.3    Forecast Trend (2023-2028)
        8.6.9    Others
    8.7    Global Intravenous Immunoglobulin Market by Distribution Channels
        8.7.1    Hospital Pharmacies
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2018-2022)
            8.7.1.3    Forecast Trend (2023-2028)
        8.7.2    Retail Pharmacies
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2018-2022)
            8.7.2.3    Forecast Trend (2023-2028)
        8.7.3    Others
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2018-2022)
            8.7.3.3    Forecast Trend (2023-2028)
    8.8    Global Intravenous Immunoglobulin Market by End Use
        8.8.1    Hospitals
            8.8.1.1    Market Share
            8.8.1.2    Historical Trend (2018-2022)
            8.8.1.3    Forecast Trend (2023-2028)
        8.8.2    Clinics
            8.8.2.1    Market Share
            8.8.2.2    Historical Trend (2018-2022)
            8.8.2.3    Forecast Trend (2023-2028)
        8.8.3    Home Care
            8.8.3.1    Market Share
            8.8.3.2    Historical Trend (2018-2022)
            8.8.3.3    Forecast Trend (2023-2028)
    8.9    Global Intravenous Immunoglobulin Market by Region
        8.9.1    North America
            8.9.1.1    Market Share
            8.9.1.2    Historical Trend (2018-2022) 
            8.9.1.3    Forecast Trend (2023-2028)
        8.9.2    Europe
            8.9.2.1    Market Share
            8.9.2.2    Historical Trend (2018-2022) 
            8.9.2.3    Forecast Trend (2023-2028)
        8.9.3    Asia Pacific
            8.9.3.1    Market Share
            8.9.3.2    Historical Trend (2018-2022) 
            8.9.3.3    Forecast Trend (2023-2028)
        8.9.4    Latin America
            8.9.4.1    Market Share
            8.9.4.2    Historical Trend (2018-2022) 
            8.9.4.3    Forecast Trend (2023-2028)
        8.9.5    Middle East and Africa
            8.9.5.1    Market Share
            8.9.5.2    Historical Trend (2018-2022) 
            8.9.5.3    Forecast Trend (2023-2028)
9    North America Market Analysis
    9.1    United States of America 
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2022) 
        9.1.3    Forecast Trend (2023-2028)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2022) 
        9.2.3    Forecast Trend (2023-2028)
10    Europe Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2022) 
        10.1.3    Forecast Trend (2023-2028)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2022) 
        10.2.3    Forecast Trend (2023-2028)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2022) 
        10.3.3    Forecast Trend (2023-2028)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2022) 
        10.4.3    Forecast Trend (2023-2028)
    10.5    Others
11    Asia Pacific Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2022) 
        11.1.3    Forecast Trend (2023-2028)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2022) 
        11.2.3    Forecast Trend (2023-2028)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2022) 
        11.3.3    Forecast Trend (2023-2028)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2022) 
        11.4.3    Forecast Trend (2023-2028)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2022) 
        11.5.3    Forecast Trend (2023-2028)
    11.6    Others
12    Latin America Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2022) 
        12.1.3    Forecast Trend (2023-2028)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2022) 
        12.2.3    Forecast Trend (2023-2028)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2022) 
        12.3.3    Forecast Trend (2023-2028)
    12.4    Others
13    Middle East and Africa Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2022) 
        13.1.3    Forecast Trend (2023-2028)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2022) 
        13.2.3    Forecast Trend (2023-2028)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2022) 
        13.3.3    Forecast Trend (2023-2028)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2022) 
        13.4.3    Forecast Trend (2023-2028)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    CSL Limited
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Grifols, S.A.
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Octapharma AG
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4    Shanghai RAAS Blood Products Co., Ltd.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Biotest AG
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.6    LFB S.A
            15.2.6.1    Company Overview
            15.2.6.2    Product Portfolio
            15.2.6.3    Demographic Reach and Achievements
            15.2.6.4    Certifications
        15.2.7    Others
16    Key Trends and Developments in the Market

 

List of Figures and Tables

1.    Global Intravenous Immunoglobulin Market: Key Industry Highlights, 2018 and 2028
2.    Global Intravenous Immunoglobulin Historical Market: Breakup by Form (USD Million), 2018-2022
3.    Global Intravenous Immunoglobulin Market Forecast: Breakup by Form (USD Million), 2023-2028
4.    Global Intravenous Immunoglobulin Historical Market: Breakup by Product (USD Million), 2018-2022
5.    Global Intravenous Immunoglobulin Market Forecast: Breakup by Product (USD Million), 2023-2028
6.    Global Intravenous Immunoglobulin Historical Market: Breakup by Indication (USD Million), 2018-2022
7.    Global Intravenous Immunoglobulin Market Forecast: Breakup by Indication (USD Million), 2023-2028
8.    Global Intravenous Immunoglobulin Historical Market: Breakup by End User (USD Million), 2018-2022
9.    Global Intravenous Immunoglobulin Market Forecast: Breakup by End User (USD Million), 2023-2028
10.    Global Intravenous Immunoglobulin Historical Market: Breakup by Region (USD Million), 2018-2022
11.    Global Intravenous Immunoglobulin Market Forecast: Breakup by Region (USD Million), 2023-2028
12.    North America Intravenous Immunoglobulin Historical Market: Breakup by Country (USD Million), 2018-2022
13.    North America Intravenous Immunoglobulin Market Forecast: Breakup by Country (USD Million), 2023-2028
14.    Europe Intravenous Immunoglobulin Historical Market: Breakup by Country (USD Million), 2018-2022
15.    Europe Intravenous Immunoglobulin Market Forecast: Breakup by Country (USD Million), 2023-2028
16.    Asia Pacific Intravenous Immunoglobulin Historical Market: Breakup by Country (USD Million), 2018-2022
17.    Asia Pacific Intravenous Immunoglobulin Market Forecast: Breakup by Country (USD Million), 2023-2028
18.    Latin America Intravenous Immunoglobulin Historical Market: Breakup by Country (USD Million), 2018-2022
19.    Latin America Intravenous Immunoglobulin Market Forecast: Breakup by Country (USD Million), 2023-2028
20.    Middle East and Africa Intravenous Immunoglobulin Historical Market: Breakup by Country (USD Million), 2018-2022
21.    Middle East and Africa Intravenous Immunoglobulin Market Forecast: Breakup by Country (USD Million), 2023-2028
22.    Global Intravenous Immunoglobulin Market Structure

Key Questions Answered in the Report

The market is expected to grow at a CAGR of 6.90% between 2023 and 2028.

The major market drivers are increasing prevalence of auto immune diseases, growing geriatric population, and technological advancements in intravenous immunoglobulin therapies.

The market is segmented based on form, product, indication, distribution channels, end use, and region.

Key trends of the market are increasing use of intravenous immunoglobulin therapies for multiple conditions, home care options for long-term and mor comfortable care, and research into methods of lowering costs of the therapy.

The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.

Key distribution channels of the market are hospital pharmacies, retail pharmacies, and others.

Key players in the global intravenous immunoglobulin market are CSL Limited, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Biotest AG, and LFB S.A, among others.

Intravenous immunoglobulin, also abbreviated as IVIG, is a therapy treatment for people who are deficient of antibodies and have weak immune systems.

Immunoglobulins are prepared from samples donated by people who have immune systems that are healthy with sufficient antibodies.

IVIG response varies from person to person, and some may not even respond to the treatment. Typically, the treatment is long-term.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER